A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab via Subcutaneous Administration in Healthy Volunteers

Study identifier:D9180C00011

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A Randomised, Single-dose, Parallel Group Study in Healthy Volunteers to Assess the Relative Bioavailability of Two Different Dosage Forms for Tozorakimab via Subcutaneous Administration

Medical condition

Healthy Participants

Phase

Phase 1

Healthy volunteers

Yes

Study drug

-

Sex

All

Estimated Enrollment

46

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 08 Apr 2024
Estimated Primary Completion Date: 05 Sept 2024
Estimated Study Completion Date: 05 Sept 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria